Experimental combo targets Hard-to-Treat lung cancer
Disease control
Completed
This early-phase trial tested a combination of two drugs—nivolumab, a standard immunotherapy, and plinabulin, an experimental drug that attacks tumor blood vessels—in 18 people with advanced non-small cell lung cancer that had worsened after chemotherapy. The main goals were to f…
Phase: PHASE1 • Sponsor: Lyudmila Bazhenova, M.D. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC